Atrium Therapeutics raises $50M PIPE at $7.93/share, extending cash runway through 2028

Atrium Therapeutics, Inc.

PIPE priced at-the-market: 5,170,384 shares at $7.93 plus pre-funded warrants for 1,134,930 shares at $7.929 each (exercise price $0.001); gross proceeds ~$50M.
Investors include Sirenia Capital Management, Aberdeen Investments, Montanova, Sessa Capital and Casdin Capital; Leerink Partners is lead placement agent with Cantor, Barclays and Wells Fargo.
Net proceeds fund development of its two lead precision-cardiology RNA product candidates, other research programs, working capital and general corporate purposes.
Company estimates proceeds plus existing cash fund operations through 2028; closing expected on or about October 9, 2026.
Post-offering common shares outstanding total 22,276,027, including shares issued to settle make-whole equity awards from the Avidity Biosciences spin-off.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.